Overview

A Study to Investigate the Pharmacokinetics of AZD2389 in Healthy Participants When Administered Alone and in Combination With Quinidine

Status:
COMPLETED

Trial end date:
2025-07-18

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the pharmacokinetics (PK) and safety of AZD2389 when administered alone and in combination with quinidine in healthy participants.

Phase:

PHASE1

Details

Lead Sponsor:

AstraZeneca

Collaborator:

Parexel

Treatments:

Quinidine